白细胞介素-31 和白细胞介素-31 受体：特应性皮炎的新治疗靶点。
Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis.
机构信息
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Translational Research Department for Skin and Brain Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.
出版信息
Exp Dermatol. 2018 Apr;27(4):327-331. doi: 10.1111/exd.13533.
Atopic dermatitis (AD) is characterized by chronic, eczematous, severe pruritic skin lesions caused by skin barrier dysfunction and T helper (Th)2 cell-mediated immunity. Interleukin (IL)-31 is a potent pruritogenic cytokine primarily produced by Th2 cells. Both IL-31 transgenic mice and wild-type mice treated with IL-31 exhibit AD-like skin lesions and scratching behaviour. IL-31 receptor α-chain (IL-31RA) is also expressed in peripheral nerves and epidermal keratinocytes, and the roles of IL-31 on pruritus and skin barrier have been investigated. Recently, an anti-IL-31 receptor antibody was shown to significantly improve pruritus in AD patients. This review focuses on IL-31 and IL-31RA in AD.
特应性皮炎（AD）的特征是慢性、湿疹样、严重瘙痒的皮肤病变，由皮肤屏障功能障碍和辅助性 T 细胞（Th）2 细胞介导的免疫引起。白细胞介素（IL）-31 是一种有效的瘙痒细胞因子，主要由 Th2 细胞产生。IL-31 转基因小鼠和用 IL-31 处理的野生型小鼠均表现出类似 AD 的皮肤损伤和搔抓行为。IL-31 受体 α 链（IL-31RA）也在周围神经和表皮角质形成细胞中表达，并且已经研究了 IL-31 在瘙痒和皮肤屏障方面的作用。最近，一种抗 IL-31 受体抗体被证明能显著改善 AD 患者的瘙痒。这篇综述重点介绍了 AD 中的 IL-31 和 IL-31RA。
Zotero 插件